Why the study?
Does pirfenidone reduce arrhythmogenic atrial remodeling and AF vulnerability in a canine model of heart failure?
Does pirfenidone reduce arrhythmogenic atrial remodeling and AF vulnerability in a canine model of heart failure?
Pirfenidone reduces arrhythmogenic atrial remodeling and AF vulnerability in a canine model of heart failure, suggesting anti-fibrotic therapy may help manage AF.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for pirfenidone in HF-related AF; prospective human trials needed before clinical adoption.
Treatment of CHF canines with PFD results in significantly reduced arrhythmogenic atrial remodeling and AF vulnerability. Pharmacological therapy targeted at the fibrotic substrate itself may play an important role in the management of AF.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: